Related Experiment Video

Updated: Jun 22, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Use of RNA aptamers for the modulation of cancer cell signaling

Sunjoo Jeong1, Hee Kyu Lee, Mee Young Kim

  • 1National Research Laboratory for RNA Cell Biology, Department of Molecular Biology, Dankook University, Gyeonggi-do, Republic of Korea.

Methods in Molecular Biology (Clifton, N.J.)
|July 2, 2009
PubMed

Insights

RNA aptamers targeting beta-catenin were developed for cancer gene therapy. These molecules inhibit oncogenic functions of beta-catenin in colon cancer cells, showing promise for effective anticancer treatments.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biotechnology

Background:

  • Cancer cells often activate unique signaling pathways, making them targets for novel therapies.
  • The Wnt/beta-catenin pathway is crucial in many human cancers, and beta-catenin is a key driver of tumorigenesis.
  • Targeting beta-catenin offers a potential strategy for effective anticancer treatments.

Purpose of the Study:

  • To select RNA aptamers that specifically bind to beta-catenin/T-Cell Factor (TCF) proteins.
  • To evaluate the potential of these RNA aptamers as intracellular therapeutic agents (intramers) for cancer gene therapy.
  • To demonstrate the inhibitory effect of RNA aptamers on the oncogenic functions of beta-catenin in colon cancer.

Main Methods:

  • Selection of RNA aptamers against beta-catenin/TCF proteins using in vitro evolution.
  • Intracellular expression of selected RNA aptamers as intramers in colon cancer cells.
  • Assessment of the impact of aptamer expression on beta-catenin's oncogenic functions.

Main Results:

  • Successfully selected RNA aptamers with high affinity and specificity for beta-catenin/TCF.
  • Demonstrated that intracellular expression of these aptamers (intramers) inhibits key oncogenic functions of beta-catenin.
  • Observed significant anti-cancer effects in colon cancer cells mediated by the aptamers.

Conclusions:

  • RNA aptamers can be effectively selected and utilized as intracellular therapeutics (intramers).
  • Targeting the beta-catenin pathway with RNA aptamers shows significant potential for colon cancer gene therapy.
  • These findings provide a proof-of-principle for developing aptamer-based anticancer gene therapies.

More Related Videos

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins11:34

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...